Kymera Therapeutics Inc
General ticker "KYMR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.4B
Kymera Therapeutics Inc follows the US Stock Market performance with the rate: 58.6%.
Estimated limits based on current volatility of 3.4%: low 38.42$, high 41.09$
Factors to consider:
- Current price 29.1% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [14.39$, 31.59$]
- 2024-12-30 to 2025-12-30 estimated range: [14.81$, 32.04$]
Financial Metrics affecting the KYMR estimates:
- Negative: Non-GAAP EPS, $ of -2.52 <= 0.10
- Negative: Operating profit margin, % of -67.81 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -7.09 <= 2.35
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term KYMR quotes
Long-term KYMR plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $72.83MM | $46.83MM | $78.59MM |
| Operating Expenses | $173.36MM | $208.08MM | $244.12MM |
| Operating Income | $-100.53MM | $-161.26MM | $-165.53MM |
| Non-Operating Income | $0.31MM | $6.45MM | $18.57MM |
| Interest Expense | $0.17MM | $0.18MM | $0.20MM |
| R&D Expense | $137.02MM | $164.25MM | $189.08MM |
| Income(Loss) | $-100.22MM | $-154.81MM | $-146.96MM |
| Profit(Loss) | $-100.22MM | $-154.81MM | $-146.96MM |
| Stockholders Equity | $459.64MM | $490.15MM | $394.97MM |
| Inventory | $8.99MM | $12.25MM | $0.00MM |
| Assets | $605.90MM | $603.13MM | $575.76MM |
| Operating Cash Flow | $-128.95MM | $-153.09MM | $-102.83MM |
| Capital expenditure | $1.60MM | $2.84MM | $34.48MM |
| Investing Cash Flow | $-99.83MM | $20.52MM | $139.89MM |
| Financing Cash Flow | $250.28MM | $153.00MM | $4.19MM |
| Earnings Per Share* | $-2.04 | $-2.82 | $-2.52 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.